John Kozarich is now serving in a new board position at Poxel SA

Jul 22, 2021
Board and Executive Moves
Background Information
Poxel SA is a biopharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, PXL770, PXL065. The company was founded by S├ębastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.